ARCH Venture Partners
A Chicago venture firm that starts and funds science-heavy biotech companies. Several of its companies work on cancer drugs, cancer cell therapies and cancer diagnostics.
Overview
ARCH Venture Partners was founded in 1986 (Wikipedia) and describes its mission as 'catalyzing discoveries that prevent, detect, and cure disease', with offices in Chicago and Seattle. Its model is company creation from academic science, often taking large early stakes and syndicating later rounds with crossover funds. Oncology is a recurring theme on the portfolio page: Agios Pharmaceuticals (gene-targeted cancer therapeutics, Nasdaq: AGIO), Akamis Bio (systemic immune oncology therapies), Arsenal Biosciences (programmable cell cancer therapies), Carrick Therapeutics, Erasca (AI-driven cancer drug discovery, Nasdaq: ERAS), Boundless Bio (ecDNA-directed therapies) and Elephas Biosciences (cancer diagnostics) are all listed.
Portfolio in OnCo (0)
Filter the startups tableNo OnCo company names this investor yet. Portfolio links are declared on the startup record (`investors`), so adding one there lists it here.
Nothing links here yet.